Suscribirse

Isolation precautions associated with COVID-19 infections among immunocompromised populations: A multicenter study of nine National Cancer Institute--designated Comprehensive Cancer Centers - 15/04/25

Doi : 10.1016/j.ajic.2025.02.002 
Marie H. Wilson, MSN, RN, CIC, FAPIC a, , Jennifer Harrington, MA, CIC b, Joanna Suh, MPH, CIC c, Candice Fearon, MSGH, BSN, RN, CIC d, Maggie Reavis, MPH, BSN, RN, CIC, CPHQ e, Suwannee Srisatidnarakul, MSN, RN, CIC f, Michelle Swetky, MPH, CIC, FAPIC a, Nancy Warren, MHA, MLT(ASCP), CIC g, Angela Badalucco, MPH, MT(ASCP) c, Caitlin M. Adams Barker, MSN, RN, CIC, FAPIC h, Shobana Nandakumar, MHA, M(ASCP), CQPA i, Steven A. Pergam, MD, MPH a
a Quality Department, Fred Hutchinson Cancer Center, Seattle, WA 
b Infection Control Department, Roswell Park Comprehensive Cancer Center, Buffalo, NY 
c Infection Prevention and Control, Karmanos Cancer Center, Detroit, MI 
d Department of Clinical Epidemiology, The James Comprehensive Cancer Center, Columbus, OH 
e Infection Prevention and Control, The University of Kansas Health System, Kansas City, KS 
f Infection Prevention and Control, City of Hope, Duarte, CA 
g Infection Control, Fox Chase Cancer Center, Philadelphia, PA 
h Quality Assurance and Safety, Dartmouth Cancer Center, Lebanon, NH 
i Infection Prevention, Duke University Medical Center, Durham, NC 

Address correspondence to Marie H. Wilson, MSN, RN, CIC, FAPIC, 1100 Fairview Ave N, Seattle, WA 98109.1100 Fairview Ave NSeattleWA98109

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Resumen

Background

Nine Comprehensive Cancer Centers sought to understand COVID-19 infection management experiences to improve future immunocompromised host guidelines.

Methods

Volunteers from Comprehensive Cancer Center Infection Prevention and Control (C3IC) completed 2 surveys on COVID-19 practices from March 2020 to December 2023. Three reviewers independently validated qualitative analysis of findings. Virtual meetings were leveraged to discuss findings and identify themes.

Results

100% (9/9) of respondents changed COVID-19-associated isolation discontinuation guidance at least once. All (9/9) included patient immune status as criterion. All (9/9) required clearance testing at some point in the pandemic, 6 of 9 (66%) continued to require clearance testing at the time of the survey. Only 1 of 9 (11%) allowed antigen testing to meet criteria. Seven isolation titles were noted across 9 institutions, despite near agreement on measures employed.

Discussion

Variability existed in COVID-19 management among study participants, despite serving similar populations, which may stem from limited data supporting understanding of viral transmissibility in immunocompromised hosts.

Conclusions

Guideline development for immunocompromised hosts, potential drivers for viral evolution, can lack clarity for consistent management of the population. Engaging subject matters in specialty populations with future guideline development will improve infection prevention in health care settings.

El texto completo de este artículo está disponible en PDF.

Highlights

COVID-19 patient management varied in study representing 16% of Comprehensive Cancer Centers.
7 labels across nine centers were used for similar isolation needs in COVID-19 patient management.
COVID-19 infection resolution inconsistently uses test of cure in Comprehensive Cancer Centers.

El texto completo de este artículo está disponible en PDF.

Key Words : Cancer, Immunosuppressed hosts, SARS-CoV-2


Esquema


 Conflicts of interest: The authors declare the following financial interests/personal relationships that may be considered as potential competing interests: One author, Steven A Pergam, reports a relationship with Global Life Technologies Corp that includes funding grants unrelated to these data or paper. He also participates in clinical trials with F2G, Mundipharma, and Symbio, none of which had any relationship to these data or paper. Other authors acknowledge volunteer leadership roles within C3IC or APIC; otherwise, authors Marie Wilson and Joanna Suh noted financial support for attending meetings or travel relative to those APIC volunteer roles. Maggie Reavis received scholarship funds to attend a conference. None of these roles or rewards had any relationship to the data or paper.
 Funding/support: This research study did not receive any specific grant or internal or external funding from agencies in the public, commercial, or not-for-profit sectors. The authors report no potential conflict of interest related to this data or study.


© 2025  Association for Professionals in Infection Control and Epidemiology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 53 - N° 5

P. 596-601 - mai 2025 Regresar al número
Artículo precedente Artículo precedente
  • Robotic versus manual disinfection of global priority pathogens at COVID-19-dedicated hospitals
  • Sayara Bista, Gopiram Syangtan, Kamal Darlami, Arun Bahadur Chand, Shrijana Bista, Mohammad Ataullah Siddiqui, Lok R. Pokhrel, Prabin Dawadi, Dev Raj Joshi
| Artículo siguiente Artículo siguiente
  • Diagnosis of coagulase-negative Staphylococcus bacteremia in patients receiving extracorporeal membrane oxygenation
  • Christian B. Wells, Erika R. O’Neil, Michal J. Sobieszczyk, Joseph E. Marcus

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.